Newsletter Tool

Today's Rundown

GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
Amgen, Biohaven, Lilly and Teva plowed plenty into marketing migraine meds. Is it working?
Private equity firms Hellman & Friedman, Bain Capital to buy Athenahealth in $17B deal
Sanifit, having put Spain's biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 data
Humana reaches value-based care deal with Minnesota-based Allina Health
Pear's digital therapeutic for alcohol use disorder bears fruit with FDA breakthrough tag
Sagent Pharmaceuticals recalls injectable seizure med thanks to familiar packaging glitch
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets
It's a wrap: Merck collects enough Acceleron shares for $11.5B buyout despite activist investor defiance
BD upsizes San Diego presence with new 220K-square-foot biosciences R&D facility
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal
UK launches review of racial, gender biases in medical devices, sparked by disproportionate COVID deaths
FDA unlocks faster clearances for future hepatitis C diagnostics
Digital MSK provider Sword Health gets $189M, boosts valuation to $1.8B

Featured Story

GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead

By Ben Adams

GlaxoSmithKline is making its first major foray into treating the fatty liver condition known as NASH as it pens a $1 billion asset pact with Arrowhead Pharmaceuticals.

Amgen, Biohaven, Lilly and Teva plowed plenty into marketing migraine meds. Is it working?

By Natalie Missakian

Pharma companies vying for a piece of the lucrative migraine market have gone all-in on marketing, turning to Olympic athletes and Hollywood stars to pitch recently approved brands in TV commercials and on social media. But is the message sinking in with patients? Apparently not yet, a new survey from Phreesia Life Sciences suggests.

Private equity firms Hellman & Friedman, Bain Capital to buy Athenahealth in $17B deal

By Heather Landi

Private equity firms Bain Capital and Hellman & Friedman LLC plan to buy Athenahealth for $17 billion, marking the second time in less than three years the health tech company has changed ownership.

Sanifit, having put Spain's biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 data

By Nick Paul Taylor

The poster child of the Spanish biotech scene has secured its exit. Having twice smashed the Spanish biotech financing record in recent years, Sanifit has now accepted a 205 million euro ($231 million) buyout bid from Vifor Pharma.

Humana reaches value-based care deal with Minnesota-based Allina Health

By Robert King

Humana announced a value-based care deal with Minnesota health system Allina Health, the latest agreement it made since becoming a direct contracting entity.

Pear's digital therapeutic for alcohol use disorder bears fruit with FDA breakthrough tag

By Andrea Park

With its proposed SPAC deal only days away from shareholder approval, Pear Therapeutics is already plotting out its future as a publicly traded company.

Sagent Pharmaceuticals recalls injectable seizure med thanks to familiar packaging glitch

By Fraiser Kansteiner

Sagent Pharmaceuticals is recalling four lots of injectable levetiracetam, which is used to treat certain types of seizures, thanks to a "lack of container closure integrity" seen in sample vials on reserve. The drug could become unsterile if the container it's stored in doesn't seal properly, Sagent explained in a recall announcement posted by the FDA.

Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets

By Ben Adams

Neurocrine Biosciences and Sosei Heptares, no strangers to major research pacts, are joining forces for a range of early- to midstage neuro assets.

It's a wrap: Merck collects enough Acceleron shares for $11.5B buyout despite activist investor defiance

By Angus Liu

Merck & Co. has consumed Acceleron Pharma. Notwithstanding clamorous activist investors, the company has collected enough Acceleron shares to complete the transaction.

BD upsizes San Diego presence with new 220K-square-foot biosciences R&D facility

By Andrea Park

BD’s life sciences footprint is about to get quite a bit bigger—220,000 square feet bigger, to be exact.

Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal

By Nick Paul Taylor

Xencor has finally found a buyer for its autoimmune disease bispecific antibody obexelimab. Almost three years after deciding to partner the drug in the wake of a failed phase 2, Xencor has offloaded the asset to Zenas BioPharma in a backloaded deal worth up to $480 million.

UK launches review of racial, gender biases in medical devices, sparked by disproportionate COVID deaths

By Andrea Park

Racial and gender biases in medical devices are "totally unacceptable," said Sajid Javid, the U.K.’s secretary of state for health and social care.

FDA unlocks faster clearances for future hepatitis C diagnostics

By Conor Hale

The FDA has eased up on makers of new diagnostic tests for hepatitis C, granting them a quicker pathway to the market. The reclassification allows diagnostic developers to seek 510(k) clearances instead of completing full premarket approval applications.

Digital MSK provider Sword Health gets $189M, boosts valuation to $1.8B

By Rebecca Torrence

Virtual MSK provider Sword Health has hit unicorn status with an additional $189 million raised, catapulting its valuation to $1.8 billion. The company has raised nearly $300 million this year alone.

PM Tracker

Featured Story

GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead

Top Stories

Amgen, Biohaven, Lilly and Teva plowed plenty into marketing migraine meds. Is it working?

Private equity firms Hellman & Friedman, Bain Capital to buy Athenahealth in $17B deal

Sanifit, having put Spain's biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 data

Humana reaches value-based care deal with Minnesota-based Allina Health

Pear's digital therapeutic for alcohol use disorder bears fruit with FDA breakthrough tag

Sagent Pharmaceuticals recalls injectable seizure med thanks to familiar packaging glitch

Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets

It's a wrap: Merck collects enough Acceleron shares for $11.5B buyout despite activist investor defiance

BD upsizes San Diego presence with new 220K-square-foot biosciences R&D facility

Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal

UK launches review of racial, gender biases in medical devices, sparked by disproportionate COVID deaths

FDA unlocks faster clearances for future hepatitis C diagnostics

Digital MSK provider Sword Health gets $189M, boosts valuation to $1.8B